New treatment option for gram-positive infections in critically III patients - Overview over linezolid;Neue therapieoption für intensivpatienten mit infektionen durch gram-positive bakterien - Überblick über linezolid

Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie

Volumn 37, Issue 4, 2002, Pages 199-204

  Krüeger, Wolfgang A ^a   Unertl, K E ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Antibiotic resistance; Linezolid; No socomial infections; Nosocomial pneumonia; Oxazolidinones

Indexed keywords

LINEZOLID; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BONE MARROW SUPPRESSION; CATHETER INFECTION; CRITICAL ILLNESS; DIALYSIS; DIARRHEA; DRUG ELIMINATION; DRUG STRUCTURE; DRUG TOLERABILITY; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NAUSEA; PNEUMONIA; PROTEIN SYNTHESIS; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

ACETAMIDES; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; CROSS INFECTION; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; OXAZOLIDINONES;

EID: 0036228582     PISSN: 09392661     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-25077     Document Type: Review

References (33)

1. The prevalence of nosocomial infection in intensive care units in Europe
2. GENARS-Projekt etabliert
3. Nosokomiale infektionen auf intensivstationen. Eine bundesweite prävalenzstudie (NIDEP)
4. Nosocomial infections in medical intensive care units in the United States
5. Verhalten bei methicillin-resistentem staphylococcus aureus (MRSA)
6. Increasing threat of Gram-positive bacterial infections in the intensive care unit setting
7. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms
8. Staphylococcus aureus with reduced susceptibility to vancomycin - United States 1997
9. Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Düsseldorf area
10. Oxazolidinones. A review
11. Linezolid
12. Linezolid resistance in a clinical isolate of Staphylococcus aureus
13. Mechanism of action of DuP 721: Inhibition of an early event during initiation of protein synthesis
14. Pharmacokinetics of linezolid in subjects with varying degrees of renal function and on dialysis
15. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement
16. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study
17. Penetration of vancomycin into human lung tissue
18. Intrapulmonary pharmaco-kinetics of linezolid
19. Randomized comparison of Linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections
20. Investigation of suspected nosocomial clusters of Staphylococcus haemolyticus infections
21. Coagulase-negative staphylococcal sepsis: New problems, few solutions. Difficult diagnosis, multiple resistance, complicate management
22. Guidelines for the management of intravascular catheter-related infections
23. Outcomes with linezolid form an ongoing compassionate use trial of patients with significant, resistant, Gram-positive infections
24. Linezolid eradicates common pathogens in community-acquired pneumonia: Summary of three studies
25. Linezolid is superior to cephalosporins in the treatment of patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia
26. Vancomycin-resistant enterococcal bacteremia: Natural history and attributable mortality
27. Hospital stay and mortality attributed to nosocomial enterococcal bacteremia: A controlled study
28. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality
29. Emergence of enterococcus as significant pathogen
30. Multidrug-resistant Enterococcus faecium. An untreatable nosocomial pathogen
31. Results of treating bacteremic patients with linezolid in a compassionate use trial for resistant, Gram-positive infections
32. In vitro activity of linezolid combined with other antibacterial agents